Journal of the American Society of Hypertension
Volume 2, Issue 3 , Pages 165-172 , May 2008

Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors

  • Ronald D. Smith, MD

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • ,
  • Hiroshi Yokoyama, MD, PhD

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • ,
  • David B. Averill, PhD

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • ,
  • Ernesto L. Schiffrin, MD, PhD

      Affiliations

    • Department of Medicine, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • ,
  • Carlos M. Ferrario, MD

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • Corresponding Author InformationCorresponding author: Carlos M. Ferrario, MD, Janeway Clinical Sciences Building, 5th Floor, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157. Tel: 336-716-0757; fax: 336-716-6644.

Received 29 August 2007 ,Revised 8 November 2007

References 

  1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289:2560–2572
  2. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347–504
  3. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension (Dual processes of remodeling and growth). Hypertension. 1993;21:391–397
  4. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation. 1999;100:2267–2275
  5. Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens. 2002;15:123S–128S
  6. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653–1659
  7. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med. 2002;113:409–418
  8. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  9. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients (A metaanalysis of 109 treatment studies). Am J Hypertens. 1992;5:95–110
  10. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003
  11. Mulvany MJ. Effects of angiotensin-converting enzyme inhibition on vascular remodeling of resistance vessels in hypertensive patients. Metabolism. 1998;47(12 suppl 1):S20–S23
  12. Rizzoni D, Porteri E, Piccoli A, et al. Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension. 1998;32:305–310
  13. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens. 2002;20:71–78
  14. Skov K, Eiskjaer H, Hansen HE, Madsen JK, Kvist S, Mulvany MJ. Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension. 2007;50:89–95
  15. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995;25:474–481
  16. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83–91
  17. Savoia C, Touyz RM, Endemann DH, et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension. 2006;48:271–277
  18. Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens. 1996;14:1247–1255
  19. Schiffrin EL, Hayoz D. How to assess vascular remodeling in small and medium-sized muscular arteries in humans. J Hypertens. 1997;15:571–584
  20. Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens. 2004;17:1192–1200
  21. Melenovsky V, Borlaug BA, Fetics B, Kessler K, Shively L, Kass DA. Estimation of central pressure augmentation using automated radial artery tonometry. J Hypertens. 2007;25:1403–1409
  22. O'Rourke MF, Adji A. An updated clinical primer on large artery mechanics: implications of pulse waveform analysis and arterial tonometry. Curr Opin Cardiol. 2005;20:275–281
  23. Smith RD, Yokoyama H, Averill DB, et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (the VIOS Study): rationale and baseline characteristics. Am J Cardiovasc Drugs. 2006;6:335–342
  24. Giles TD. Blood pressure goals for hypertension guidelines: what is wrong with “optimal”?. J Clin Hypertens (Greenwich). 2006;8:835–839
  25. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685–1697
  26. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20:1461–1464
  27. Mathiassen ON, Buus NH, Larsen ML, Mulvany MJ, Christensen KL. Small artery structure adapts to vasodilatation rather than to blood pressure during antihypertensive treatment. J Hypertens. 2007;25:1027–1034
  28. Heagerty AM. Predicting hypertension complications from small artery structure. J Hypertens. 2007;25:939–940
  29. Schiffrin EL, Pu Q, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens. 2002;15:105–110
  30. Thybo NK, Korsgaard N, Eriksen S, Christensen KL, Mulvany MJ. Dose-dependent effects of perindopril on blood pressure and small-artery structure. Hypertension. 1994;23:659–666
  31. Izzard AS, Rizzoni D, Gabiti-Rosei E, Heagerty AM. Small artery structure and hypertension: adaptive changes and target organ damage. J Hypertens. 2005;23:247–250
  32. Mathiassen ON, Buus NH, Sihm I, et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens. 2007;25:1021–1026
  33. Rizzoni D, Porteri E, Boari GE, et al. Prognostic significance of small-artery structure in hypertension. Circulation. 2003;108:2230–2235
  34. Yokoyama H, Averill DB, Brosnihan KB, Smith RD, Schiffrin EL, Ferrario CM. Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens. 2005;18:922–929
  35. Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with non-insulin-dependent diabetes mellitus. Hypertension. 2005;45:659–665
  36. Sihm I, Schroeder AP, Aalkjaer C, Mulvany MJ, Thygesen K, Lederballe O. Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. Am J Hypertens. 1998;11:263–271
  37. Rizzoni D, Palombo C, Porteri E, et al. Relationships between coronary flow vasodilator capacity and small artery remodeling in hypertensive patients. J Hypertens. 2003;21:625–631
  38. De Ciuceis C, Porteri E, Rizzoni D, et al. Structural alterations of subcutaneous small-resistance arteries may predict major cardiovascular events in patients with hypertension. Am J Hypertens. 2007;20:846–852
  39. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951–958

 This study was supported by an unrestricted grant and study medications from Daiichi Sankyo, Inc. The authors gratefully acknowledge grant support, in part, provided by Unifi, Inc., Greensboro, NC, and the Farley-Hudson Foundation, Jacksonville, NC.

 Conflict of interest: none.

PII: S1933-1711(07)00243-4

doi: 10.1016/j.jash.2007.11.001

Journal of the American Society of Hypertension
Volume 2, Issue 3 , Pages 165-172 , May 2008

Article Tools

* Image Usage & Resolution